Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) rose 29.4% during trading on Saturday . The company traded as high as C$0.11 and last traded at C$0.11. Approximately 602,760 shares changed hands during trading, an increase of 511% from the average daily volume of 98,700 shares. The stock had previously closed at C$0.09.
Hemostemix Stock Performance
The stock’s fifty day simple moving average is C$0.09 and its 200-day simple moving average is C$0.10. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The company has a market capitalization of C$20.73 million, a PE ratio of -4.07 and a beta of 1.25.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Featured Stories
- Five stocks we like better than Hemostemix
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- NEW LAW: Congress Approves Setup For Digital Dollar?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
